vTv Therapeutics (NASDAQ:VTVT) Stock, Quote.Headers.trade-ideas

vTv Therapeutics

vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Itsproduct pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.

VTVT

Biotech

News

Health Care

Movers

Trading Ideas

General

vTv Therapeutics&#39; Phase 3 trial for cadisegliatin in type 1 diabetes resumes after FDA lifts hold, with a revised six-month timeline to accelerate key studies.

FDA Lifts Clinical Hold On vTv Therapeutics&#39; Phase 3 Diabetes Trial, Stock Surges

Wall Street

Eurozone

Commodities

Intraday Update

Markets

CGTX

LIPO

NLSP

VERO

VTYX

Dow Edges Lower; Ventyx Biosciences Shares Plummet

movers image

AVXL

BMRC

CERO

COMM

COUR

CPTN

CTRI

IART

ITRG

LGVN

LUXH

MESO

NIPG

NISN

NOVA

NUWE

OPTT

PGHL

PHIO

PYPD

RNLX

SERV

TIVC

TNDM

TSLA

TWOU

YIBO

Why Bank of Marin Bancorp Shares Are Trading Lower? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics Inc

Press Releases

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF PANCREATIC CANCER

CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING

vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

Earnings

vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update

vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate Update

vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

Management

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Agenus

Alterity Therapeutics Limited - American Depositary Shares

Alterity Therapeutics

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

Connect Biopharma Holdings Limited - American Depositary Shares

Connect Biopharma Hldgs

Citius Oncology

Dyadic International, Inc. - Common Stock

Dyadic International

Fortress Biotech

Forte Biosciences

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

iBio

ImmuCell

Immix Biopharma

Immuneering Corporation - Class A Common Stock

Immuneering

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Kronos Bio

MAIA Biotechnology

OKYO Pharma

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

Rein Therapeutics

Repare Therapeutics

Serina Therapeutics

Spero Therapeutics

X4 Pharmaceuticals

Alliance Global Partners

HC Wainwright & Co.

Northland Capital Markets

Comments

vTv Therapeutics

vTv Therapeutics (NASDAQ:VTVT) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga